Lifecore Biomedical
LFCR
97 hedge funds and large institutions have $279M invested in Lifecore Biomedical in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 33 reducing their positions, and 12 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.74% less ownership
Funds ownership: 87.83% → 87.09% (-0.74%)
3% less capital invested
Capital invested by funds: $287M → $279M (-$8.04M)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 98 → 97 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wynnefield Capital
New York
|
+$4.31M |
| 2 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$3.51M |
| 3 |
ICM
ISZO Capital Management
New York
|
+$2.8M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.28M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$941K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$7.82M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$4.46M |
| 3 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$2.83M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.12M |
| 5 |
BlackRock
New York
|
-$599K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
101
Perritt Capital Management
Chicago,
Illinois
| – | -$297K | -26,750 | Closed |
|
102
Squarepoint
New York
| – | -$170K | -15,349 | Closed |
|
|
TI
103
Trexquant Investment
Stamford,
Connecticut
| – | -$140K | -12,624 | Closed |
|
|
JF
104
Jump Financial
Chicago,
Illinois
| – | -$119K | -10,756 | Closed |
|
105
Lazard Asset Management
New York
| – | -$73K | -6,655 | Closed |
|
|
CWS
106
Confluence Wealth Services
Mcmurray,
Pennsylvania
| – | -$19K | -1,745 | Closed |
|
107
Marshall Wace
London,
United Kingdom
| – | -$1K | -104 | Closed |
|
LFCR Hedge Fund Activity: Q1 2022 in Review
97 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2022, worth a combined $279M — down 2.8% from $287M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LFCR and 11 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 34 added.
The largest buyer was Wynnefield Capital, adding an estimated $4.31M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $7.82M sold.
- 97 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2022, down from 98 in Q4 2021.
- Funds reported $279M of Lifecore Biomedical stock for Q1 2022, down 2.8% quarter-over-quarter.
- 11 funds opened new Lifecore Biomedical positions in Q1 2022 and 12 closed out, a net change of -1 holder.
- The largest Lifecore Biomedical buyer in Q1 2022 was Wynnefield Capital, an estimated $4.31M added.
- The largest Lifecore Biomedical seller in Q1 2022 was Kennedy Capital Management, an estimated $7.82M sold.
Based on aggregated 13F filings for Q1 2022.